$1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much Today
Halozyme Therapeutics (NASDAQ:HALO) has outperformed the market over the past 15 years by 8.16% on an annualized basis producing an average annual return of 21.6%. Currently, Halozyme Therapeutics has a market
Halozyme grew much faster than the overall stock market over 15 years. When a company has a long track record of strong growth, it suggests investors believe in its business and future plans.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.